Diffuse Fatty Atrophy of the Pancreas: Causes, Consequences & Management

Definition

Replacement of pancreatic parenchyma (acinar & islet cells) by adipose tissue, resulting in loss of exocrine and endocrine function. Also called pancreatic lipomatosis or non-alcoholic fatty pancreas disease (NAFPD).

Etiology & Risk Factors

Category	Mechanisms
Metabolic	Obesity, insulin resistance, type 2 diabetes, metabolic syndrome, dyslipidemia
Chronic Pancreatitis	Recurrent inflammation → fibrosis + fatty replacement (alcohol, genetic, obstructive)
Aging	Physiologic fatty infiltration >60 yr; ↑ with sarcopenia
Genetic	CFTR, SPINK1, PRSS1 variants; lipodystrophy syndromes
Iatrogenic	Glucocorticoids, chemotherapy, post-radiation
Anatomic	Pancreatic duct obstruction, post-surgical (Whipple)

Clinical Consequences

Exocrine Insufficiency (EPI)

• Maldigestion: steatorrhea, weight loss, bloating, fat-soluble vitamin deficiency (A, D, E, K).
• Fecal elastase-1 <200 μg/g (severe <100).

Endocrine Dysfunction

• Impaired β-cell mass → insulin deficiency → diabetes (type 3c / pancreatogenic).
• α-cell loss → impaired glucagon counter-regulation → hypoglycemia risk.
• Incidence: 30–50% develop diabetes over 10–20 years.

Association with Neoplasia

• NAFPD linked to ↑ risk of pancreatic adenocarcinoma (shared risk factors + inflammatory milieu).
• Surveillance not routinely recommended but consider in high-risk (genetic, strong FHx).

Diagnosis

• Imaging: CT (fat attenuation <−10 HU), MRI (chemical shift – signal loss on out-of-phase), EUS (hyperechoic parenchyma).
• Quantification: Fat fraction (%) via MRI-PDFF (gold standard); >5–6% abnormal.
• Functional tests: Fecal elastase, mixed-meal tolerance test, C-peptide.

Management

Exocrine

• Pancreatic enzyme replacement therapy (PERT): enteric-coated microspheres (lipase 40,000–50,000 U/meal).
• PPI may improve enzyme survival.
• Fat-soluble vitamin supplementation (monitor levels).

Endocrine

• Diabetes management per type 3c guidelines: insulin often needed early; avoid sulfonylureas (hypoglycemia risk); GLP-1 RA / SGLT2i if appropriate.
• Monitor HbA1c q3–6mo.

Disease Modification

• Weight loss (if obese) → ↓ pancreatic fat, ↑ insulin sensitivity.
• Alcohol cessation.
• Optimize metabolic syndrome components.
• Treat underlying chronic pancreatitis (endoscopic/stenting/surgical).

Follow-Up

• Annual fecal elastase, HbA1c, fat-soluble vitamins.
• Interval imaging if concern for neoplasm (new mass, duct dilation, weight loss).